Clinical Trial Update: A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II [Phase 2]

View source ↗

Summary

This document notes the withdrawal of the Phase 2 RETAIN trial of Aralast NP in new-onset Type 1 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Aralast NP (alpha1-antitrypsin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: WITHDRAWN